Trial Outcomes & Findings for Efficacy of the Quell Wearable Device for Fibromyalgia (NCT NCT03714425)
NCT ID: NCT03714425
Last Updated: 2022-08-15
Results Overview
The questionnaire reflects a patient's belief about the efficacy of treatment. The Patients' Global Impression of Change (PGIC) is a 7-point scale (1-7) depicting a patient's rating of overall improvement. Patients rate their change as 1="very much improved," 2="much improved," 3="minimally improved," 4="no change," 5="minimally worse," 6="much worse," or 7="very much worse." Lower values represent a better outcome.
COMPLETED
NA
119 participants
3 months
2022-08-15
Participant Flow
Participant milestones
| Measure |
High Frequency Device
Subjects will use high frequency Quell devices.
Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
|
Low Frequency Device
Subjects will use low frequency Quell devices.
Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
|
|---|---|---|
|
Overall Study
STARTED
|
62
|
57
|
|
Overall Study
COMPLETED
|
55
|
46
|
|
Overall Study
NOT COMPLETED
|
7
|
11
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Efficacy of the Quell Wearable Device for Fibromyalgia
Baseline characteristics by cohort
| Measure |
High Frequency Device
n=62 Participants
Subjects will use high frequency Quell devices.
Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
|
Low Frequency Device
n=57 Participants
Subjects will use low frequency Quell devices.
Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
|
Total
n=119 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
57 Participants
n=99 Participants
|
52 Participants
n=107 Participants
|
109 Participants
n=206 Participants
|
|
Age, Categorical
>=65 years
|
5 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
10 Participants
n=206 Participants
|
|
Age, Continuous
|
48.3 years
STANDARD_DEVIATION 13.1 • n=99 Participants
|
52.3 years
STANDARD_DEVIATION 13.8 • n=107 Participants
|
50.4 years
STANDARD_DEVIATION 13.5 • n=206 Participants
|
|
Sex: Female, Male
Female
|
58 Participants
n=99 Participants
|
53 Participants
n=107 Participants
|
111 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
4 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
8 Participants
n=206 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
1 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Asian
|
1 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Black or African American
|
5 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
10 Participants
n=206 Participants
|
|
Race (NIH/OMB)
White
|
48 Participants
n=99 Participants
|
47 Participants
n=107 Participants
|
95 Participants
n=206 Participants
|
|
Race (NIH/OMB)
More than one race
|
7 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
11 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Region of Enrollment
United States
|
62 participants
n=99 Participants
|
57 participants
n=107 Participants
|
119 participants
n=206 Participants
|
PRIMARY outcome
Timeframe: 3 monthsThe questionnaire reflects a patient's belief about the efficacy of treatment. The Patients' Global Impression of Change (PGIC) is a 7-point scale (1-7) depicting a patient's rating of overall improvement. Patients rate their change as 1="very much improved," 2="much improved," 3="minimally improved," 4="no change," 5="minimally worse," 6="much worse," or 7="very much worse." Lower values represent a better outcome.
Outcome measures
| Measure |
High Frequency Device
n=62 Participants
Subjects will use high frequency Quell devices.
Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
|
Low Frequency Device
n=57 Participants
Subjects will use low frequency Quell devices.
Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
|
|---|---|---|
|
Patients' Global Impression of Change
|
3.58 score on a scale
Interval 3.09 to 4.07
|
3.24 score on a scale
Interval 2.74 to 3.75
|
SECONDARY outcome
Timeframe: Baseline, 3 monthsThe Brief Pain Inventory assesses the severity of pain and its impact on functioning. Pain Severity Score is calculated by adding the scores for questions 2, 3, 4 and 5 and then dividing by 4. This gives a severity score out of 10 (0-10), where 0 means no pain and 10 is worst possible pain. Pain Interference Score is calculated by adding the scores for questions 8a, b, c, d, e, f and g and then dividing by 7. This gives an interference score out of 10 (0-10), where 0 means does not interfere and 10 means completely interferes. Lower values represent a better outcome.
Outcome measures
| Measure |
High Frequency Device
n=62 Participants
Subjects will use high frequency Quell devices.
Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
|
Low Frequency Device
n=57 Participants
Subjects will use low frequency Quell devices.
Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
|
|---|---|---|
|
The Brief Pain Inventory
|
5.8 score on a scale
Standard Deviation 1.6
|
5.5 score on a scale
Standard Deviation 1.5
|
SECONDARY outcome
Timeframe: Baseline, 3 monthsThe Revised Fibromyalgia Impact Questionnaire (FIQR) is an assessment and evaluation instrument developed to measure fibromyalgia (FM) patient status, progress and outcomes. The FIQR has 3 domains: function, overall impact and symptoms. FIQR has 21 individual questions and all questions are based on an 11-point numeric rating scale of 0 to 10, with 10 being 'worst'. The summed score for function (range 0 to 90) is divided by 3, the summed score for overall impact (range 0 to 20) is not changed, and the summed score for symptoms (range 0 to 100) is divided by 2. The total FIQR is the sum of the three domain scores. The total score of the FIQR ranges from 0 to 100. Lower values represent a better outcome.
Outcome measures
| Measure |
High Frequency Device
n=62 Participants
Subjects will use high frequency Quell devices.
Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
|
Low Frequency Device
n=57 Participants
Subjects will use low frequency Quell devices.
Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
|
|---|---|---|
|
Revised Fibromyalgia Impact Questionnaire
|
61.3 score on a scale
Standard Deviation 16.3
|
52.8 score on a scale
Standard Deviation 17.3
|
SECONDARY outcome
Timeframe: Baseline, 3 monthsThe Pain Catastrophizing Scale (PCS) instructions ask participants to reflect on past painful experiences, and to indicate the degree to which they experienced each of 13 thoughts or feelings when experiencing pain, on 5-point scales with the end points (0) not at all and (4) all the time. The total score is computed by summing responses to all 13 items (scale 0-4). PCS total scores range from 0 - 52. The higher the score, the more catastrophizing thoughts are present. Lower values represent a better outcome.
Outcome measures
| Measure |
High Frequency Device
n=62 Participants
Subjects will use high frequency Quell devices.
Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
|
Low Frequency Device
n=57 Participants
Subjects will use low frequency Quell devices.
Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
|
|---|---|---|
|
Pain Catastrophizing Scale
|
21.5 score on a scale
Standard Deviation 13.2
|
17.8 score on a scale
Standard Deviation 12.3
|
SECONDARY outcome
Timeframe: Baseline, 3 monthsThe Pain Disability Index is a simple and rapid instrument for measuring the impact that pain has on the ability of a person to participate in essential life activities. The total score is a sum of all 7 categories of life activity listed. A score of 0 means no disability at all, and a score of 10 signifies that all of the activities in which people would normally be involved have been totally disrupted or prevented by the pain. The total index ranges from 0 to 70. The higher the index the greater the person's disability due to pain. Lower values represent a better outcome.
Outcome measures
| Measure |
High Frequency Device
n=62 Participants
Subjects will use high frequency Quell devices.
Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
|
Low Frequency Device
n=57 Participants
Subjects will use low frequency Quell devices.
Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
|
|---|---|---|
|
Pain Disability Index
|
39.4 score on a scale
Standard Deviation 15.6
|
34.6 score on a scale
Standard Deviation 15.5
|
SECONDARY outcome
Timeframe: Baseline, 3 monthsThe Hospital Anxiety and Depression Scale (HADS) was developed to assess depression and anxiety in patients. Responses are rated on a scale from 0 to 3, with higher scores indicating higher severity. The ratings of the 14 items are summed to yield a total score (0 to 42), or for each subscale separately (0 to 21). 0 to 7 for normal or no anxiety/depression, 8 to 10 for mild, 11 to 14 for moderate, and 12 to 21 for severe anxiety/depression. Lower values represent a better outcome.
Outcome measures
| Measure |
High Frequency Device
n=62 Participants
Subjects will use high frequency Quell devices.
Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
|
Low Frequency Device
n=57 Participants
Subjects will use low frequency Quell devices.
Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
|
|---|---|---|
|
Hospital Anxiety and Depression Scale
|
18.5 score on a scale
Standard Deviation 7.3
|
15.8 score on a scale
Standard Deviation 7.6
|
SECONDARY outcome
Timeframe: Post-treatment at 3 monthsSelf-report rating "How helpful was the TENS for your fibromyalgia?" 0=not at all helpful, 10=very helpful.
Outcome measures
| Measure |
High Frequency Device
n=62 Participants
Subjects will use high frequency Quell devices.
Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
|
Low Frequency Device
n=57 Participants
Subjects will use low frequency Quell devices.
Quell: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
|
|---|---|---|
|
Helpfulness Rating
|
4.8 score on a scale
Standard Deviation 3.5
|
4.8 score on a scale
Standard Deviation 2.6
|
Adverse Events
High Frequency Device
Low Frequency Device
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place